Funding Round attributes
Alpha-9 Oncology, a clinical-stage biotechnology company specializing in radiopharmaceuticals, announced it has raised $175 million in an oversubscribed Series C financing round. The funding aims to accelerate the development of its diverse pipeline of radiopharmaceutical therapies designed for the treatment of cancer.
Founded with a mission to develop novel therapeutics targeting cancer, Alpha-9 Oncology focuses on creating precision radiopharmaceuticals. These treatments harness radioactive isotopes to target and destroy cancer cells while minimizing damage to surrounding healthy tissues. The company's pipeline includes several promising candidates aimed at addressing various types of cancer, from solid tumors to other aggressive forms of the disease.
The Series C round attracted significant attention from a range of institutional investors. It was co-led by EcoR1 Capital and Frazier Life Sciences. Other participants in the round included well-known healthcare investors such as Samsara BioCapital, BVF Partners L.P., Deep Track Capital, and Deerfield Management. This substantial financial backing reflects the growing interest and confidence in the potential of Alpha-9 Oncology’s approach to cancer treatment.
